 | Up a level |
Baertsch, M., Wuchter, P., Schlenzka, J., Weisel, K., Noppeney, R., Martin, H., Lindemann, H., Haenel, M., Nogai, A., Scheid, C., Salwender, H., Fenk, R., Graeven, U., Reimer, P., Schmidt-Hieber, M., Goerner, M., Schmidt-Wolf, I., Klein, S., Ho, A. and Goldschmidt, H. (2015). EFFICIENCY AND TOXICITY OF CYCLOPHOSPHAMIDE BASED STEM CELL MOBILIZATION IN RELAPSED MULTIPLE MYELOMA PATIENTS: OBSERVATIONS FROM THE ONGOING PHASE III TRIAL RELAPSE. Haematologica, 100. S. 258 - 260. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Mai, E. K., Hielscher, T., Bertsch, U., Schlenzka, J., Salwender, H. J., Munder, M., Gerecke, C., Pfreundschuh, M., Duehrsen, U., Brossart, P., Neben, K., Hillengass, J., Raab, M. S., Hose, D., Merz, M., Breitkreutz, I., Jauch, A., Martin, H., Lindemann, H. -W., Scheid, C., Weisel, K. C., Blau, I. W. and Goldschmidt, H. (2017). Prediction of early overall and infection-related mortality during induction therapy in transplant-eligible multiple myeloma - a pooled analysis from three GMMG phase III trials. Oncol. Res. Treat., 40. S. 36 - 38. BASEL: KARGER. ISSN 2296-5262